DelveInsight's 'Anaplastic Lymphoma Kinase (ALK) Positive - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Anaplastic Lymphoma Kinase (ALK) Positive epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Anaplastic Lymphoma Kinase (ALK) Positive epidemiology report gives a thorough understanding of the Anaplastic Lymphoma Kinase (ALK) Positive by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Anaplastic Lymphoma Kinase (ALK) Positive in the US, Europe, and Japan. The report covers the detailed information of the Anaplastic Lymphoma Kinase (ALK) Positive epidemiology scenario in seven major countries (US, EU5, and Japan).
The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Anaplastic Lymphoma Kinase (ALK) Positive epidemiology covered in the report provides historical as well as forecasted Anaplastic Lymphoma Kinase (ALK) Positive epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Anaplastic Lymphoma Kinase (ALK) Positive report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Anaplastic Lymphoma Kinase (ALK) Positive
3. Anaplastic Lymphoma Kinase (ALK) Positive: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Anaplastic Lymphoma Kinase (ALK) Positive Treatment and Management
6.2. Anaplastic Lymphoma Kinase (ALK) Positive Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in 7MM (2017-2030)
Table 2 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United States (2017-2030)
Table 4 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Germany (2017-2030)
Table 6 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in France (2017-2030)
Table 8 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Italy (2017-2030)
Table 10 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Spain (2017-2030)
Table 12 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United Kingdom (2017-2030)
Table 14 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Japan (2017-2030)
Table 16 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in 7MM (2017-2030)
Figure 2 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United States (2017-2030)
Figure 4 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Germany (2017-2030)
Figure 6 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in France (2017-2030)
Figure 8 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Italy (2017-2030)
Figure 10 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Spain (2017-2030)
Figure 12 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in the United Kingdom (2017-2030)
Figure 14 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Anaplastic Lymphoma Kinase (ALK) Positive Epidemiology in Japan (2017-2030)
Figure 16 Anaplastic Lymphoma Kinase (ALK) Positive Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
